Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 4 · 57.1%Moderate 1 · 14.3%High 1 · 14.3%

Adjunctive antioxidants for schizophrenia vs placebo

Global state: improvement, short term PANSS · patients with schizophrenia

Adjunctive antioxidants for schizophrenia showed no clear difference in global state: improvement, short term PANSS compared with placebo (low certainty).

1 finding from 1 review

Antioxidant treatments for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.77 [0.53, 1.12]
3 studies · 229 participants
Low

Adjunctive antioxidants for schizophrenia vs placebo

Mental state: General ‐ average total score (PANSS, high = poor) ‐ up to 12 weeks (short‐term) · patients with schizophrenia

1 finding from 1 review

Antioxidant treatments for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 584 participants
Very low

Adjunctive antioxidants for schizophrenia vs placebo

Mental state · patients with schizophrenia

1 finding from 1 review

Antioxidant treatments for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 843 participants
Low

Adjunctive antioxidants for schizophrenia vs placebo

General functioning ‐ short term GAS · patients with schizophrenia

1 finding from 1 review

Antioxidant treatments for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 52 participants
Low

Adjunctive antioxidants for schizophrenia vs placebo

General functioning ‐ medium term GAS · patients with schizophrenia

1 finding from 1 review

Antioxidant treatments for schizophrenia 2016 · Cochrane Headline outcomes only
no estimate extracted
1 study · 135 participants
High

Adjunctive antioxidants for schizophrenia vs placebo

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

Adjunctive antioxidants for schizophrenia showed no clear difference in leaving the study early, short term compared with placebo (moderate certainty).

1 finding from 1 review

Antioxidant treatments for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.73 [0.48, 1.11]
16 studies · 1584 participants
Moderate

Adjunctive antioxidants for schizophrenia vs placebo

Adverse effects: 1. Serious (any time point) ‐ any serious adverse effect Various methods · patients with schizophrenia

Adjunctive antioxidants for schizophrenia showed no clear difference in adverse effects: 1. Serious (any time point) ‐ any serious adverse… compared with placebo (low certainty).

1 finding from 1 review

Antioxidant treatments for schizophrenia 2016 · Cochrane Headline outcomes only
RR 0.65 [0.19, 2.27]
3 studies · 234 participants
Low